This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170417005298/en/

Mr. Gemignani’s career in healthcare spans over three decades, including senior management positions at several pharmaceutical and biopharmaceutical companies. Most recently, he served as Chief Executive Officer and Chief Financial Officer of
“We are very fortunate to have
“I am thrilled to join Synergy at such a transformative time in the company’s history,” said
Gary Gemignani’s appointment as EVP and CFO comes with the announcement of the impending retirement of
“Bernard has been an outstanding contributor to our success,” added Dr. Jacob. “He helped build the strong financial foundation that has supported our ongoing evolution from a successful research and development company to a fully integrated commercial organization. We appreciate his dedication to Synergy and are pleased he will continue to serve the company during this time of transition.”
About
Synergy is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts on analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. Synergy’s proprietary GI platform includes one commercial product TRULANCE™ (plecanatide) and a second lead product candidate, dolcanatide. For more information, please visit www.synergypharma.com.
Forward-Looking Statement
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to
View source version on businesswire.com: http://www.businesswire.com/news/home/20170417005298/en/
VP, Investor Relations and Corporate Communications
ghopkins@synergypharma.com
Source:
H.C. Wainwright & Co. Ranked #1 Placement Agent by Sagient Research Systems
TechnipFMC Updates First Quarter 2017 Earnings Teleconference Schedule
More Articles